PMDA — authorised 4 July 2014
- Marketing authorisation holder: GLAXOSMITHKLINE K.K.
- Status: approved
PMDA authorised Incruse Ellipta on 4 July 2014
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 4 July 2014.
GLAXOSMITHKLINE K.K. holds the Japanese marketing authorisation.